N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec.
Nigel talks us through the update highlights, explains why companies working with siRNA are much more open to using novel delivery systems, the strong commercial point of difference for Nuvec® and the next steps for N4 Pharma.
N4 Pharma Plc is a specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines.
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.
